According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…
According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…
The biopharmaceutical company Complexa, Inc., has announced that the first patient has been dosed on the Phase 2 clinical trial FIRSTx. FIRSTx is a study of the experimental drug CXA-10…
The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…
Research into graft-versus-host-disease (GVHD), a condition that can occur after bone marrow transplants, has yielded promising results. A study, reported by BrightSurf, found that a particular group of microRNA molecules involved…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
